文献速递胸部肿瘤

靶向非小细胞肺癌EGFR外显子20插入突变:近期进展与临床更新

Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates.
PubMed 文献 · Cancer Discov · 2021-07-23

本文综述EGFR外显子20插入突变(EGFR ins20)的分子与临床病理特征,并总结针对该亚型NSCLC的新兴治疗数据。EGFR ins20约占EGFR激活突变的10%,对早期EGFR酪氨酸激酶抑制剂(TKI)敏感性不如del19和L858R等经典突变。近年靶向EGFR ins20的进展及更有效的识别改善了该亚型患者的治疗开发能力。

要点

  • EGFR ins20约占EGFR激活突变的10%,对早期EGFR TKI敏感性低于经典突变。
  • EGFR ins20突变多样性及常规基因分型识别困难导致其频率被低估。
  • 近年靶向EGFR ins20的新兴治疗及更有效识别提升了该亚型治疗开发能力。

核心结论

  • EGFR ins20曾因对早期EGFR TKI不敏感而被归为不可靶向或 intrinsic 耐药亚群,但近期靶向进展与更有效识别增强了开发有效疗法的能力。

研究设计与样本

  • 本文为综述,描述EGFR ins20突变的分子和临床病理特征,并总结该亚型EGFR突变NSCLC患者新兴治疗的近期数据。

主要发现

  • 约10%的EGFR激活突变为EGFR激酶结构域外显子20的框内插入突变(EGFR ins20)。
  • EGFR ins20突变对早期EGFR TKI的敏感性不如del19和L858R等经典激活突变。
  • EGFR外显子20内突变多样性及常规临床基因分型检测识别困难导致其频率被低估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Approximately 10% of EGFR-activating mutations occur as in-frame insertion mutations in exon 20 of the EGFR kinase domain (EGFR ins20). EGFR ins20 mutations have not demonstrated the same sensitivity to early generations of EGFR tyrosine kinase inhibitors (TKI) as canonical activating EGFR mutations such as del19 and L858R. Development of effective therapies for this subset of patients has been challenging, but recent years have seen more rapid progress in these efforts. In this review, we describe the molecular and clinicopathologic features of EGFR ins20 mutations and summarize recent data on emerging therapies for patients with this subtype of EGFR-mutant non-small cell lung cancer (NSCLC). SIGNIFICANCE: When activating mutations in EGFR were first discovered in lung cancer, the lack of sensitivity of tumors harboring EGFR ins20 mutations to early-generation EGFR TKIs resulted in this subset of EGFR-mutant tumors being initially classified as an untargetable or intrinsically resistant subpopulation. In addition, the diversity of mutations within EGFR exon 20 and resultant challenges identifying them on routine clinical genotyping tests led to underestimation of their frequency. However, recent scientific progress in targeting EGFR ins20 mutations as well as more effective identification of this clinical cohort has enhanced our ability to develop effective therapies for patients with this subtype of EGFR-mutant NSCLC.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Meador CB, Sequist LV, Piotrowska Z, et al. Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates. Cancer Discov. 2021. PMID: 34301786. doi:10.1158/2159-8290.CD-21-0226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。